Several other equities analysts have also issued reports on VSTM. Royal Bank of Canada began coverage on Verastem in a research report on Thursday, April 14th. They set an “outperform” rating and a $5.00 price target on the stock. Zacks Investment Research upgraded Verastem from a “sell” rating to a “hold” rating in a research report on Tuesday, April 26th. HC Wainwright reiterated a “buy” rating on shares of Verastem in a research report on Tuesday, March 29th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Verastem in a research report on Friday, April 1st. Finally, Truist Financial began coverage on Verastem in a research report on Wednesday, March 9th. They issued a “buy” rating and a $6.00 price objective on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, Verastem presently has an average rating of “Buy” and a consensus target price of $5.63.
Shares of Verastem stock opened at $1.08 on Thursday. The company has a current ratio of 6.72, a quick ratio of 5.69 and a debt-to-equity ratio of 0.34. The firm has a market capitalization of $201.27 million, a PE ratio of -2.63 and a beta of 0.88. The business’s 50-day moving average price is $1.41 and its 200-day moving average price is $1.83. Verastem has a 12 month low of $1.00 and a 12 month high of $4.94.
Several institutional investors and hedge funds have recently added to or reduced their stakes in VSTM. BVF Inc. IL lifted its stake in shares of Verastem by 32.7% in the 3rd quarter. BVF Inc. IL now owns 14,977,258 shares of the biopharmaceutical company’s stock valued at $46,130,000 after purchasing an additional 3,691,000 shares during the period. BioImpact Capital LLC purchased a new position in shares of Verastem in the 3rd quarter valued at approximately $8,701,000. Eagle Asset Management Inc. lifted its stake in shares of Verastem by 176.8% in the 4th quarter. Eagle Asset Management Inc. now owns 4,393,080 shares of the biopharmaceutical company’s stock valued at $9,093,000 after purchasing an additional 2,805,850 shares during the period. Soleus Capital Management L.P. purchased a new position in Verastem during the fourth quarter valued at $3,371,000. Finally, Renaissance Technologies LLC raised its stake in Verastem by 190.2% during the first quarter. Renaissance Technologies LLC now owns 1,684,106 shares of the biopharmaceutical company’s stock valued at $2,375,000 after buying an additional 1,103,806 shares during the last quarter. Institutional investors own 73.25% of the company’s stock.
Verastem Company Profile (Get Rating)
Verastem, Inc, a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK.
- Get a free copy of the StockNews.com research report on Verastem (VSTM)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.